caa a22 4500 46578996X CHVBK 20180323112021.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF00198594 doi (NATIONALLICENCE)springer-10.1007/BF00198594 Phase II trial of vinblastine in advanced ovarian carcinoma [Elektronische Daten] A Gynecologic Oncology Group study [Gregory Sutton, John Blessing, Mark Adelson, Parviz Hanjani] Summary: A phase II trial of vinblastine in patients with refractory epithelial ovarian adenocarcinoma of the ovary was conducted by the Gynecologic Oncology Group (GOG) between March 9, 1988 and July 7, 1988. Vinblastine was administered in a dose of 9 mg/m2 intravenously every three weeks until disease progression or toxicity supervened. Twenty patients were entered initially. One was ineligible due to a previous primary cancer. Thus, 19 patients are evaluable for toxicity and response. All patients had cisplatin-combination chemotherapy and four had prior radiotherapy. Median age was 63 years (range 40-75 years). Thirteen patients had disease in the pelvis and six had extrapelvic metastases. Ten patients had grade 3 lesions and seven had grade 2. A median of two courses (range: 1-6) were administered. Toxicity was moderate. Seven patients (36.8%) experienced GOG grade 3 or 4 leukocytopenia and six had grade 3 or 4 granulocytopenia. Median nadir WBC was 2,000 cells/μ1 (range 600-3,500) and platelet nadirs for the three patients with thrombocytopenia were 60,000, 116,000, and 147,000. Other toxicity included grade 3 gastrointestinal and renal toxicity in one patient each. Seven patients (36.8%) had stable disease on therapy and 12 had increasing disease. No responses were observed. Vinblastine in this dose and schedule is inactive in patients with resistant epithelial ovarian adenocarcinoma progressing on first-line chemotherapy. Kluwer Academic Publishers, 1990 vinblastine nationallicence ovarian carcinoma nationallicence Sutton Gregory Section of Gynecologic Oncology, Indiana University Medical School, Indianapolis, IN, USA aut Blessing John Gynecologic Oncology Group, Cancer Research Scientist VI, Roswell Park Memorial Institute, Buffalo, NY, USA aut Adelson Mark Department of Obstetrics and Gynecology, State University of New York Health Science Center, Syracuse, NY, USA aut Hanjani Parviz Section of Pelvic Oncology, Temple University Health Science Center, Philadelphia, PA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 377-379 0167-6997 8:4<377 1990 8 10637 https://doi.org/10.1007/BF00198594 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00198594 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sutton Gregory Section of Gynecologic Oncology, Indiana University Medical School, Indianapolis, IN, USA aut NATIONALLICENCE 700 1- Blessing John Gynecologic Oncology Group, Cancer Research Scientist VI, Roswell Park Memorial Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Adelson Mark Department of Obstetrics and Gynecology, State University of New York Health Science Center, Syracuse, NY, USA aut NATIONALLICENCE 700 1- Hanjani Parviz Section of Pelvic Oncology, Temple University Health Science Center, Philadelphia, PA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 377-379 0167-6997 8:4<377 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer